Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

The protective activity of noscapine on renal ischemia–reperfusion injury in male Wistar rat

Document Type : Original Article

Authors
Mehrangiz Khanmoradi 1
Seyyed Ali Mard 2
Nahid Aboutaleb 1
Malihe Nobakht 3
Masoud Mahmoudian 4
1 Physiology Research Center and Phyiology Department, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 Physiology Research Center (PRC), Research Institute for Infectious Diseases of Digestive System and Department of Physiology, School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
10.22038/ijbms.2014.2581
Abstract
Objective(s):Bradykinin is a part of the kinin-kallikreinsystem which is involved in ischemia-reperfusion injury via B1 and B2 receptors.Noscapine is a non-competitive antagonist of bradykinin receptors. Noscapine has been reported to to be able to protect some organs against ischemia-reperfusion injury but its effect on renal ischemia-reperfusion injury (RIR) in rats is unknown. Therefore, the present study was designed to evaluate the effect of noscapine on renal ischemia-reperfusion injury in rats.
Materials and Methods: Twenty four rats were randomly assigned to four groups; sham, RIR control, pre-and post-treatment with noscapine. To induce RIR injury, 20 days after right nephrectomy, animals underwent a midline laparotomy and the renal artery was clamped for 40 min to induce ischemia, and the clamp was then removed to allow reperfusion for 48 hr. Animals received noscapine or vehicle 1 hr before RIR or just prior to reperfusion. At the end of the experiment, animals were killed by cardiac exsanguination. Blood samples were collected to assess blood urea nitrogen (BUN) and creatinine. The kidneys were also removed for histopathlogical and western-blot analysis.
Results: Noscapine treatment 1 hr before RIR or just prior to reperfusion protects the renal tissue structure as compared with the control. The expression levels of the studied inflammatory mediators, TNF-α and MCP-1in pretreated-, and treated-noscapine groups decreased as compared with the control group. The levels of BUN and creatinine in pre-, and post-treated noscapine groups were significantly lower than in control animals.
Conclusion: Noscapine protects renal tissue structure and function against RIR through down-regulation of the inflammatory mediators.
Keywords
BUN
Creatinine
Noscapine
Rat
Renal ischemia-reperfusion injury
1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715–2729.
2. Naka Y, Roy DK, Smerling AJ, Michler RE, Smith CR, Stern DM, Oz MC, Pinsky DJ. Inhaled nitric oxide fails to confer the pulmonary protection provided by distal stimulation of the nitric oxide pathway at the level of cyclic guanosine monophosphate. J Thorac Cardiovasc Surg 1995; 110:1434 –1441.
3. Hashimoto N, Takeyoshi I, Tsutsumi H, Sunose Y, Tokumine M, Totsuka O, et al. Effects of a bradykinin B(2) receptor antagonist on ischemia–reperfusion injury in a canine lung transplantation model. J Heart Lung Transplant 2004; 23:606–613.
4. Totsuka O, Takeyoshi I, Tsutsumi H, Hashimoto N, Sunose Y, Tokumine M, et al. The effects of                          a bradykinin B2 receptor antagonist in extended           liver resection with ischemia in dogs. Hepatogastroenterology 2004; 51:1771–1775.
5. Souza DG, Pinho V, Pesquero JL, Lomez ES, Poole S, Juliano L, et al. Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury. Br J Pharmacol 2003; 139:129–139.
6. Arakawa K, Takeyoshi I, Akao Y, Totsuka O, Matsumoto K, Morishita Y. Bradykinin B2 receptor antagonist FR173657 ameliorates small bowel ischemia-reperfusion injury in dogs. Dig Dis Sci 2005; 50:27-36.
 7. Chiang WC, Chien CT, Lin WW, Lin SL, Chen YM, Lai CF, et al. Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med 2006; 41:1304-1314.
 8. Mahmoudian M, Siadatpour Z, Ziai SA, Mehrpour M, Benaissa F, Nobakht M., Reduction of the prenatal hypoxic-ischemic brain edema with noscapine. Acta Physiol Hung 2003; 90:313-318.
9. Solez K, Racusen LC, Whelton A. Glomerular epithelial cell changes in early postischemic acute renal failure in rabbits and man. Am J Pathol 1981; 103:163-173.
10. Villanueva S, Céspedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 2006; 290:R861-870.
11. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991; 102:774-777.
12. Mahmoudian M, Mehrpour M, Benaissa F, Siadatpour Z. A preliminary report on the application of noscapine in the treatment of stroke. Eur J Clin Pharmacol 2003; 59:579-581.
13. Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49:217-225.
14. Zughaier S, Karna P, Stephens D, Aneja R. Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogs. PLoS One 2010; 11:e9165.
15. Ebrahimi SA, Zareie MR, Rostami P, Mahmoudian M. Interaction of noscapine with the bradykinin mediation of the cough response. Acta Physiol Hung 2003; 90:147-155.
16. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, et al. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007; 60:831-839.
17. Zhou J, Gupta K, Aggarwal S, Aneja R, Chandra R, Panda D, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003; 63:799-807.
18. Tomasoni S, Azzollini N, Casiraghi F, Capogrossi MC, Remuzzi G, Benigni A. CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J Am Soc Nephrol 2000; 11:747–752.
19. Wolf G, Aberle S, Thaiss F, Nelson PJ, Krensky AM, Neilson EG, et al.  TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. Kidney Int1993; 44:795-804.
20. Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R, et al. Association of TGFbeta1, TNF-alpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. 
BMC Med Genet 2007; 12:20.
21. Jiang S, Tang Q, Rong R, Tang L, Xu M, Lu J, et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur J Pharmacol 2012; 688:56-61.
22. Jia Y, Zhao Z, Xu M, Zhao T, Qiu Y, Ooi Y, et al. Prevention of renal ischemia-reperfusion injury by short hairpin RNA of endothelin A receptor in a rat model. Exp Biol Med 2012; 1:894-902.